An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

NCT05907057 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Ivosidenib 500mg Oral Tablet
DRUG: Azacitidine

Sponsor

Servier Affaires Médicales